The Dow Jones index closed higher by more than 200 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Red Robin The Trade: Red Robin Gourmet Burgers, Inc. RRGB Presi ...

The integration of Twill's condition-specific, expert-led peer groups will enhance the member experience and deepen engagement with Dario's proven cardiometabolic solution NEW YORK, Sept. 12, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market announced today the integration of condition-specific communities and peer groups with personalized navigation capabilities into its cardiometabolic solution to improve outcomes-based engagemen ...

New Research Confirms the Benefit of Dario's Integrated, Data-Driven Approach to Health and Chronic Condition Management NEW YORK, Sept. 10, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market announced today the publication of a new study in the peer-reviewed journal Frontiers in Endocrinology. The study demonstrates the effectiveness of Dario's cardiometabolic solution for members living with diabetes or prediabetes and depression. ...

DarioHealth Corp. (NASDAQ:DRIO) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Kat Parrella - Investor Relations Manager Erez Raphael - Chief Executive Officer Steven Nelson - Chief Commercial Officer Conference Call Participants Lucas Romanski - TD Cowen Operator Good morning, ladies and gentlemen, and welcome to the DarioHealth Second Quarter 2024 Results Conference Call. At this time, all lines are in a listen-only mode. After the presentation we will conduct the question- ...

DarioHealth Corp. (DRIO) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.29 per share. This compares to loss of $0.58 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 120.69%. A quarter ago, it was expected that this company would post a loss of $0.59 per share when it actually produced a loss of $0.20, delivering a surprise of 66.10%. Over the last four quarters, the c ...

Financial Performance - Total revenues for Q2 2024 reached $6,255,000, a slight increase of 1.68% compared to $6,152,000 in Q2 2023[14]. - Gross profit for Q2 2024 was $2,756,000, up from $2,074,000 in Q2 2023, representing a 32.9% increase[14]. - Operating expenses increased to $18,947,000 in Q2 2024, compared to $16,094,000 in Q2 2023, reflecting a 17.3% rise[14]. - The net loss for Q2 2024 was $13,610,000, an improvement from a net loss of $16,585,000 in Q2 2023, indicating a 17.8% reduction in losses[14]. - For the six months ended June 30, 2024, the company reported a net loss of $20,785, compared to a net loss of $29,410 for the same period in 2023, indicating an improvement in financial performance[18]. - The company’s total revenues for the six months ended June 30, 2024, were $12.013 million, compared to $13.218 million for the same period in 2023[61]. - The net loss for the six months ended June 30, 2024, was $20,785, a decrease of $8,625 compared to a net loss of $29,410 for the same period in 2023[150]. Assets and Liabilities - Total assets increased to $122,134,000 as of June 30, 2024, compared to $96,389,000 on December 31, 2023, representing a growth of approximately 26.7%[9]. - Total current liabilities rose to $17,416,000 from $12,493,000, an increase of about 39.0%[12]. - Stockholders' equity increased to $68,055,000 from $58,144,000, reflecting a growth of approximately 16.9%[13]. - Cash and cash equivalents decreased to $22,938,000 from $36,797,000, a decline of about 37.7%[9]. - The accumulated deficit as of June 30, 2024, stands at $363,474, reflecting the ongoing financial challenges faced by the company[22]. - The company experienced a cash outflow of $24,473 from operating activities for the six months ended June 30, 2024, compared to an outflow of $14,393 in the prior year[18]. Revenue Recognition and Accounting - The Company recognizes revenue from tangible hardware upon transfer of control, typically at shipment, and recognizes revenue from fixed-price services ratably over the contract period[32]. - Revenue from the newly acquired Twill platform is recognized over time, as customers simultaneously receive and consume the benefits provided by the Company's performance[35]. - The Company applies ASC 606 for revenue recognition, which includes identifying contracts, performance obligations, and determining transaction prices[29]. - The balance of deferred revenues as of June 30, 2024, was $1,515, with an expected recognition of approximately $1,426 over the next 12 months[63]. Acquisitions and Partnerships - The company entered into a merger agreement with Twill, Inc., aiming to enhance its digital therapeutics offerings and expand its market reach[21]. - The acquisition of Twill was completed for a total consideration of $34.456 million, including $10 million in cash and various stock options and warrants[46][49][51]. - The total purchase price allocation for Twill included $19.435 million in identified intangible assets, with $5.644 million attributed to technology and $13.791 million to customer relationships[50]. - The Company has entered into contracts with a preferred partner and a health plan provider for data license and implementation services, expanding its strategic partnerships[37]. Stock and Equity - The company reported stock-based compensation of $10,420 for the six months ended June 30, 2024, compared to $10,148 in the prior year[18]. - The total stock-based compensation expenses for the six months ended June 30, 2024, were $10,420, compared to $10,148 for the same period in 2023[111]. - The total number of potential common shares related to outstanding options, warrants, and preferred shares excluded from diluted net loss per share calculations was 33,782,788 as of June 30, 2024[114]. Operational Challenges - The company has incurred recurring losses and negative cash flows since inception, which raises substantial doubt about its ability to continue as a going concern for the next twelve months[23]. - The company believes its current cash on hand will not be sufficient to fund projected operating requirements for one year, raising substantial doubt about its ability to continue as a going concern[184][185]. - The company has a significant present need for capital to scale up commercial launches and meet sales targets[165]. - The company expects to continue generating losses for the foreseeable future due to insufficient recurring revenue sources[151]. Market and Economic Conditions - The company’s operations may be adversely affected by political, economic, and military instability in Israel, including the ongoing conflict with Hamas[176][178]. - The company’s commercial insurance does not cover losses from events associated with war and terrorism, which could materially affect its business[181]. - The market price of the company's common stock has fluctuated between a high of $2.55 and a low of $0.92 from January 1, 2024, to August 2, 2024[187]. - The company has not experienced material changes in financial condition or results of operations that would explain the stock price volatility during the specified period[187].

NEW YORK, July 30, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it will release its financial results for the 2nd quarter ended June 30th, 2024, on Thursday, August 8th, 2024, before the market opens and will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call. Date: Thursday, August 8th, 8:30am ET Call me™: ht ...

The employer, a leader in environmental services, selected Dario's cardiometabolic suite to address multiple health conditions, including diabetes, pre-diabetes, hypertension and weight management needs, including integrated support for those employees taking a GLP-1 medication. Dario's proven ability to drive sustainable behavior change is key to helping employees achieve successful outcomes while taking a GLP-1, as research shows that 68% of people stop taking these medications within a year, putting them ...

New research confirms behavior change driven by Dario digital platform is sustainable for 12 month period and supports clinical results for members taking a GLP-1 Adopting healthy behaviors while taking a GLP-1 is crucial for the efficacy of the drug. The sustainability of these behaviors is proven to be achievable through the innovative technology behind Dario's cardiometabolic solution and integrated tools for GLP-1 medications. Sustainable behavior change allows users to continue to realize healthy outco ...

After two decades of successfully scaling multiple healthcare companies, Steven Nelson joins DarioHealth as Chief Commercial Officer to accelerate revenue growth across the health plans, employers and pharma channels NEW YORK, June 5, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario", "DarioHealth" or the "Company"), a leader in the global digital health market, announced today a strategic reorganization designed to streamline leadership and focus the organization on accelerating its commercial ...